Head-To-Head Survey: Solventum (NYSE:SOLV) vs. Biodesix (NASDAQ:BDSX)

Solventum (NYSE:SOLV) and Biodesix (NASDAQ:BDSX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, valuation and risk.

Profitability

This table compares Solventum and Biodesix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Solventum	18.69%	25.26%	7.40%
Biodesix	-39.85%	-1,760.83%	-40.28%

Earnings and Valuation

This table compares Solventum and Biodesix”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solventum	$8.33 billion	1.39	$1.56 billion	$8.87	7.53
Biodesix	$88.50 million	1.27	-$35.26 million	($4.85)	-2.28

Solventum has higher revenue and earnings than Biodesix. Biodesix is trading at a lower price-to-earnings ratio than Solventum, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Solventum has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500. Comparatively, Biodesix has a beta of 0.43, suggesting that its stock price is 57% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations for Solventum and Biodesix, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solventum	1	5	7	0	2.46
Biodesix	1	0	5	0	2.67

Solventum presently has a consensus price target of $89.45, suggesting a potential upside of 33.95%. Biodesix has a consensus price target of $32.50, suggesting a potential upside of 193.32%. Given Biodesix’s stronger consensus rating and higher possible upside, analysts clearly believe Biodesix is more favorable than Solventum.

Institutional & Insider Ownership

21.0% of Biodesix shares are owned by institutional investors. 0.2% of Solventum shares are owned by company insiders. Comparatively, 23.2% of Biodesix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Solventum beats Biodesix on 10 of the 14 factors compared between the two stocks.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. The Dental Solutions segment provides a comprehensive suite of dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents. The Health Information Systems provides software solutions including computer-assisted, physician documentation, direct-to-bill and coding automation, classification methodologies, speech, recognition, and data visualization platforms. The Purification and Filtration segment provides purification and filtration technologies including filters, purifiers, cartridges, and membranes. The company was incorporated in 2023 and is based in Saint Paul, Minnesota.

About Biodesix

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.